All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Lorlatinib Improves PFS, Reduces CNS Progression in Advanced ALK+ NSCLC

November 2nd 2022

Lorlatinib improved progression-free survival and reduced 12-month cumulative incidence of central nervous system progression compared with crizotinib in patients with advanced ALK-positive non–small cell lung cancer irrespective of brain metastases at baseline.

Telisotuzumab Vedotin Plus Erlotinib Shows Encouraging Activity in Advanced c-Met+ NSCLC

November 1st 2022

Telisotuzumab vedotin in combination with erlotinib induced promising outcomes in patients with advanced, EGFR-mutated, c-MET-positive non–small cell lung cancer who were contraindicated for surgery or other approved therapies.

FOLFIRINOX Provides Prolonged PFS Benefit Over Gemcitabine in Locally Advanced Pancreatic Carcinoma

November 1st 2022

Treatment with FOLFIRINOX resulted in a significantly longer progression-free survival than that achieved with gemcitabine in patients with locally advanced pancreatic carcinoma, meeting the primary end point of the phase 3 NEOPAN trial.

BCMA and CD3 T-cell–Engaging Bispecific Antibody Shows Promise in R/R Multiple Myeloma

November 1st 2022

ABBV-383 was effective and well tolerated at all administered doses in patients with relapsed/refractory multiple myeloma, according to safety and efficacy results from an ongoing first-in-human, phase 1 dose-escalation/-expansion study.

New Center for Experimental Therapeutics in Cancer Advances Promising Treatments

November 1st 2022

Center will serve as a hub for commercialization of promising cancer therapies.

First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLL

November 1st 2022

The first patient in the chronic lymphocytic leukemia cohort has been dosed in the phase 1 COVALENT-101 trial, which is evaluating the first-in-class covalent menin inhibitor BMF-219.

European Commission Grants Orphan Drug Designation to Selinexor for Myelofibrosis

November 1st 2022

The European Commission has granted an orphan drug designation to selinexor for the treatment of patients with myelofibrosis.

Cracking the “MGUS” Code Reveals Monoclonal Gammopathy of Clinical Significance:

November 1st 2022

When assessing monoclonal gammopathy it is important to rule out clinically significant associations requiring treatment.

Trastuzumab Deruxtecan Produces Activity in Metastatic Breast Cancer With Brain Mets, Irrespective of HER2 Status

November 1st 2022

Fam-trastuzumab deruxtecan-nxki induced meaningful antitumor activity in patients with HER2-positive, HER2-low, or HER2-negative metastatic breast cancer who presented with brain metastases at baseline.

ODAC Votes Against Omburtamab for Pediatric Metastatic Neuroblastoma

October 31st 2022

In a 16 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee voted that sufficient evidence has not been provided to conclude that 131I-omburtamab improves overall survival for pediatric patients with central nervous system /leptomeningeal metastases from neuroblastoma.

FDA Grants Fast Track Designation to MT-101 for CD5+ Relapsed/Refractory PTCL

October 31st 2022

The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma.

Thoracic Experts Review ESMO 2022 Data in NSCLC

October 31st 2022

In a special OncLive video program, The Board, D. Ross Camidge, MD, PhD, led a discussion regarding key abstracts that were presented during the 2022 ESMO Congress in non–small cell lung cancer.

Treatment Opportunities Expand for HER2+ Breast Cancer With Brain Metastases

October 31st 2022

Suchita Pakkala, MD, discussed how treatments like tucatinib and fam-trastuzumab deruxtecan-nxki have widened the armamentarium for patients with brain metastases; the importance of enrolling these patients in clinical trials; and what future treatment sequencing might look like for this population.

Iomab-B Conditioning Elicits Durable CR in Relapsed/Refractory AML

October 31st 2022

Reduced-intensity conditioning treatment plus Iomab-B prior to bone marrow transplant led to a durable and statistically significant 6-month complete remission rate vs conventional care in older patients with active, relapsed/refractory acute myeloid leukemia.

Luspatercept Improves Transfusion Independence in Very Low– to Intermediate-Risk MDS

October 31st 2022

Luspatercept generated a statistically significant improvement in red blood cell transfusion independence with concurrent hemoglobin increase vs epoetin alfa in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who require RBC transfusions, meeting the primary end point of the phase 3 COMMANDS trial.

CRC Tumor Sidedness Plays an Increasing Role in Clinical Practice

October 31st 2022

Prognosis, treatment outcomes, and molecular characteristics have become associated with sidedness in colorectal cancers making the distinction an essential characteristic for consideration in decison-making.

Genetics May Predict Bladder Cancer Immunotherapy Response

October 31st 2022

Cedars-Sinai cancer researchers identify new biomarkers linked with patient response to immunotherapy for many types of cancers.

Sunvozertinib Showcases Early Safety, Efficacy in EGFR Exon 20–Mutated NSCLC

October 30th 2022

D. Ross Camidge, MD, PhD, discusses the potential utility of sunvozertinib in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations, the efficacy and safety data observed with the agent, and future research directions.

Genomic Testing and ctDNA Add to Personalized Treatment Approach in Metastatic CRC

October 29th 2022

Benjamin Adam Weinberg, MD, discussed the expanding role of circulating tumor DNA in CRC and the various testing methods, the utilization of liquid biopsies, and the need for up-front genetic testing to identify molecular alterations.

FDA/European Approval Sought for Epcoritamab in Relapsed/Refractory LBCL/DLBCL

October 28th 2022

A biologics license application has been submitted to the FDA seeking the approval of subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma or diffuse large B-cell lymphoma after 2 or more lines of systemic therapy.